Recently, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) announced the appointment of Dr. Xuedong Dai as Executive Vice President of International Discovery Service Unit.
Dr. Xuedong Dai, Ph.D. in Organic Chemistry and Postdoctoral at MIT, has been deeply involved in the research and development of chemical drugs for central nervous system diseases, infectious diseases and tumor diseases for more than 20 years. Dr. Dai has a deep understanding and rich experience in the process of drug discovery, including the identification and optimization of seed compounds, and the development of high-quality clinical candidate compounds. Dr. Dai participated in the research and development of drugs including marketed drugs, such as Horizant®/Regnite®; clinical drugs, such as JNJ-75276617; and clinical candidate compounds, such as Arbaclofen Placarbil, XP21279, XP23829, etc.
Prior to joining Medicilon, Dr. Dai served as senior executives in many big pharmaceutical companies globally, such as Xi’an Janssen, HD Biosciences, GSK, and Xenoport, which accumulated excellent and Dr. Dai has excellent project management records and rich management experience.
“I am very pleased that Dr. Dai has joined Medicilon.” Dr. Chunlin Chen, founder and CEO of Medicilon, said: “Dr. Dai has an international vision and innovative thinking on innovative drug research and development, and has unique advantages in developing overseas markets and entering the international pharmaceutical market. I believe that Dr. Dai, as the Executive Vice President of the International Discovery Service Unit, will bring development momentum to Medicilon, empower global customers to develop new drugs even faster and better, and promote Medicilon’s business to a higher level. “
Dr. Dai said: “I very much agree with Medicilon’s vision and development strategy, and I also admire Medicilon’s persistent pursuit of innovative drug research and development over the past 17 years. While Medicilon continues to strengthen its independent R&D and innovation capabilities, it has also reached strategic collaboration with many big pharmaceutical companies globally. This is an important point that attracted me to join Medicilon. I am full of confidence in the future of Medicilon and look forward to working with the team to help the global innovative drug research and development. “
The mission of Medicilon International Discovery Service Unit is to provide high quality, efficient and cost-effective synthetic chemistry, drug design, and new drug candidate compound services to global pharmaceutical companies. We are stride to meet the research and development needs of the clients in various chemical fields of pre-clinical new drug research, shorten the cycle of drug R&D, and reduce the cost of drug R&D.
Medicilon International Discovery Service Unit has a management team and lab personnel with a rich background of studying abroad, a world-leading synthesis and analysis laboratory with installed state-of-the-art instruments and equipment. In order to provide clients with better services, the International Discovery Service Unit keeps up with new developments and new technologies in drug design and synthesis, such as artificial intelligence/machine learning (AI/ML), proteolysis targeting chimera (PROTAC), antibody-drug conjugates (ADC), direct functionalization of inert carbon-hydrogen bonds, photoredox reactions, and flow chemistry, etc.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 900 clients globally. Medicilon is proud to contribute to human health in the globe.
marketing@medicilon.com
